Rossari Q1 revenue up 28% to ₹6,972M; profit rises but dips sequentially
Revenue rose 28% YoY, net profit edged up to ₹351M from ₹336M. Sequential profit fell 24% due to seasonal fluctuations. Board approved trivial ESOP and subsidiary transfer.
— 1 earlier story on Rossari Biotech Ltd. →What's new
- Revenue up 28% YoY to ₹6,972M; net profit ₹351M vs ₹336M a year ago.
- Sequential profit fell from ₹460M in March quarter due to seasonal factors.
- Board approved 4,000 ESOP grant and transfer of subsidiary to Rossari Singapore for ₹24Cr.
Why this matters
Q1 results are solid but routine: year-on-year growth is strong, but the sequential profit dip is normal seasonality. The board items are immaterial. No surprise in the print; estimates are unlikely to shift.
What we're watching
- Sustained revenue growth the rest of FY27.
- Margin trajectory as volumes normalise.
- Any new client wins or product expansions.
The full read
Rossari Biotech’s June-quarter revenue hit ₹6,972M, up 28% year on year. Net profit rose to ₹351M from ₹336M a year ago. Against the March quarter, however, revenue inched up just 2% while profit dropped 24% — management blamed normal seasonality. The board also approved two trivial items: an ESOP grant of 4,000 options and an internal subsidiary transfer worth ₹24 crore that has no cash-flow or valuation impact. The print is solid but unexciting; analyst notes call it routine. For a stock at 19.9x trailing earnings with 11.5% ROE, the next catalyst is likely outside this quarter's numbers.
Questions answered
- Why did profit fall sequentially despite higher revenue?
- Seasonal fluctuations: Q4 typically has higher margins due to year-end sales mix, while Q1 incurs higher costs. Revenue was flat sequentially, but profit dropped from ₹460M to ₹351M.
- What is the subsidiary restructuring about?
- Rossari is transferring its wholly owned subsidiary Rossari International Limited Company to another wholly owned unit, Rossari (Singapore) Pte. Ltd., valued at about ₹24 crore. This consolidates overseas holdings under one platform.
- How much was the ESOP and share allotment?
- The board approved a grant of 4,000 employee stock options and allotted 2,500 equity shares upon exercise. These are negligible relative to total equity.
- Was there any guidance or outlook?
- No. The filing contained only quarterly numbers and routine board items. Analyst notes indicate results were in line with market expectations.
Rossari Biotech Ltd.
Latest quarter · Jun 2026
Strength & growth
Story so far
All notes on ROSSARI →- 18 Jul 2026 · 4:35 PM IST Rossari Q1 revenue up 28% to ₹6,972M; profit rises but dips sequentially
- 1d ago Rossari's margin slips to 11.6%, but management says that's the floor.